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Abstract
Background: Assisted injecting has been associated with increased risk of blood-borne infections, overdose, and
other harms among people who inject drugs (PWID), particularly women. Given the changing availability of relevant
harm reduction interventions in Vancouver, Canada, in recent years, we conducted a gender-based analysis to
examine changes in rates and correlates of assisted injecting over time among active PWID.
Methods: Using data from a prospective cohort of PWID in Vancouver, we employed gender-stratified multivariable
generalized estimating equations to examine trends in assisted injecting and identify the correlates during two
periods: June 2006–November 2009 and December 2009–May 2014.
Results: Among 1119 participants, 376 (33.6 %) were females. Rates of assisted injecting declined between 2006
and 2014 among males (21.9 to 13.8 %) and females (37.0 to 25.6 %). In multivariable analyses, calendar year of
interview also remained independently and negatively associated with assisted injecting among males (adjusted
odds ratio [AOR] 0.95, 95 % confidence interval [CI] 0.92–0.99) and females (AOR 0.93, 95 % CI 0.89–0.97). Syringe
borrowing remained independently associated with assisted injecting throughout the study period among females
(AOR 1.53, 95 % CI 1.10–2.11 during 2006–2009; AOR 2.15, 95 % CI 1.24–3.74 during 2009–2014) and during
2009–2014 among males (AOR 1.88, 95 % CI 1.02–3.48).
Conclusions: Our findings demonstrate assisted injecting has significantly decreased for both males and
females over the past decade. Nevertheless, rates of assisted injecting remain high, especially among women,
and are associated with high-risk behavior, indicating a need to provide safer assisted injecting services to
these vulnerable sub-populations of PWID.
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Background
Injection drug use is a major public health issue associ-
ated with significant health and social consequences.
People who require assistance injecting have been shown
to be a particularly vulnerable subgroup of people who
inject drugs (PWID) [1, 2]. Assisted injection, which re-
fers to manual administration of an injection to another
person [3], is common among PWID, with a 1996–2002
study estimating that 41 % of PWID in a large Canadian
city reported assisted injecting within the previous
6 months [1].
Assisted injecting is a major risk factor for many nega-
tive health outcomes. As those who provide assistance
injecting often use the same syringe between two indi-
viduals, there is an independent association between
requiring help injecting and syringe sharing—a well-
established risk behavior for blood-borne infections [4,
5]. Research has documented that assisted injecting is
strongly associated with HIV [1, 6, 7], hepatitis C [8],
and cutaneous injection-related infections [9]. One
Canadian study found a twofold higher risk of HIV in-
fection among those requiring assistance injecting [1].
The negative health consequences of assisted injecting
are not only limited to infections but also include non-
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fatal overdoses [10] and vulnerability to various forms of
violence (e.g., robbery) [11].
Previous research has indicated that female PWID
may be more likely than males to require assistance with
injecting [1, 2, 4, 12]. The higher rates of assisted inject-
ing among females may be due to social and interper-
sonal dynamics where males often control the use of
drugs within relationships [1, 6, 11, 13, 14]. Conse-
quently, females are commonly injected by males [11],
and in turn, many women report requiring assistance
with injecting due to a lack of knowledge on how to in-
ject themselves [2]. Although the reasons for needing as-
sistance with injecting may be highly gendered, common
reasons for assisted injecting include a lack of viable
veins, reliance upon jugular injection, being in with-
drawal, and a lack of knowledge of how to inject [2, 4].
In Vancouver, Canada, some harm reduction strategies
have been implemented over the past decade to address
the harms associated with assisted injecting. In Septem-
ber 2003, a medically supervised injection facility (SIF)
opened in the city’s Downtown Eastside neighborhood,
an area with high levels of injection drug use and HIV
infection [15]. There, healthcare staff provides education
on safer injection techniques [16]; however, the laws
governing the SIF do not allow healthcare staff and peers
to perform manual assistance with injecting, constituting
a significant barrier for some PWID who are unable to
self-inject [11]. In response, in 2005, the Vancouver Area
Network of Drug Users (VANDU), a local drug user
organization, began operating the Injection Support
Team (IST) whereby trained peer volunteers walked the
streets of the Downtown Eastside providing education,
support, and assistance with injections [3]. However, it
ceased operating in 2009 due to a lack of funding. Sub-
sequently, between 2011 and 2013, a peer-run unsanc-
tioned SIF was operated by VANDU in the Downtown
Eastside, where trained peer volunteers provided assisted
injections under a strict harm reduction policy ensuring
safe injection practices; however, compared to IST, it was
on a smaller scale [11]. In many settings around the world,
except for some European countries, liabilities related to
providing assistance with injecting of illicit drugs pose
challenges for developing harm reduction interventions
other than provision of safer injection education [17].
While a recent study has suggested a declining impact
of assisted injecting on HIV incidence in Vancouver
[18], little is known about changes in the prevalence and
the associated harms of assisted injection over time in
this setting, and how they may differ across the genders.
Therefore, we conducted a gender-based analysis among
PWID in Vancouver to examine trends in the rates of re-
quiring assisted injecting over time. In sub-analyses, we
also examined changes in the correlates of and reasons
for requiring assisted injecting over time.
Methods
Study design
Data were collected from the Vancouver Injection Drug
Users Study (VIDUS), a prospective cohort study of
PWID in Vancouver, Canada. Recruitment of VIDUS
participants began in the Downtown Eastside neighbor-
hood in May 1996. The VIDUS cohort has been de-
scribed in detail previously [19]. In brief, eligibility
criteria include being aged ≥18 years, injecting illicit
drugs at least once in the preceding month, living in
greater Vancouver area, and providing informed consent.
At baseline and subsequent semi-annual follow-up inter-
views, participants complete an interviewer-administered
questionnaire, which includes items on sociodemo-
graphics, drug use patterns, and other characteristics
and exposures. At each visit, participants provide blood
samples to test for HIV and hepatitis C and receive CAD
$30 in monetary compensation. The VIDUS cohort has
been approved by the University of British Columbia/
Providence Healthcare Research Ethics Board.
For the present analyses, participants were eligible if
they completed the baseline assessment between Decem-
ber 1, 2005 and May 31, 2014. The sample was further
restricted to those who reported having injected drugs in
the previous 6 months for each subsequent follow-up.
Study variables
The main outcome of interest was assisted injecting in
the past 6 months, defined as responding “yes” to the
question: “In the last 6 months, did someone help you
inject?” The primary explanatory variable was calendar
year of interview (per year later). Based on the literature
[2, 4, 20], we also selected a range of secondary explana-
tory variables that we hypothesized to be associated with
assisted injecting. Binary variables (yes vs. no) included
the following: Caucasian ancestry; not completing high
school education; currently in a stable relationship;
homelessness; sex work, defined as exchanging sex for
gifts, food, shelter, clothes, etc.; incarceration; and being
a victim of violence; ≥daily heroin injection; ≥daily
cocaine injection; ≥daily crystal methamphetamine injec-
tion; ≥daily prescription opioid injection; any public in-
jection drug use; syringe borrowing; non-fatal overdose;
and ever learned safe injection technique by a healthcare
provider assessed at baseline. A continuous variable
included years injecting (per 10 years longer). Time-
varying sociodemographic and drug use variables referred
to the previous 6 months unless otherwise indicated.
Statistical analyses
All analyses were stratified by gender. First, we examined
the baseline sample characteristics stratified by reports of
assisted injecting using Pearson’s chi-squared test (for bin-
ary variables) and Wilcoxon rank-sum test (for continuous
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variables). Fisher’s exact test was used when one or more
of the cells contained expected values less than or equal to
five. We also plotted proportions of participants reporting
assisted injecting over the calendar year of interview.
Since the analyses of assisted injecting included serial
measures for each participant, we used generalized esti-
mating equations (GEE) with logit link, which provided
standard errors adjusted by multiple observations per
person using an exchangeable correlation structure. To
examine the relationship between the calendar year of
interview and assisted injecting, we fit multivariable GEE
models using a conservative confounding model selec-
tion approach [21]. We included all variables that were
associated with assisted injecting in unadjusted analyses
at p < 0.10 in a full multivariable model, and used a step-
wise approach to fit a series of reduced models. After
comparing the value of the coefficient of the calendar
year of interview in each reduced model, we dropped
the secondary variable associated with the smallest rela-
tive change. We continued this iterative process until
the minimum change exceeded 5 %.
Because each participant contributed a different num-
ber of study visits, we further conducted a sensitivity
analysis using independence estimating equations (IEE)
with the same confounding model selection approach.
IEE examined the relationship between the calendar year
of interview and assisted injecting, allowing for potential
informative cluster size in the analysis [22].
In a sub-analysis to identify changes in the correlates
of assisted injecting over time, we divided the study
period into two sub-periods (June 2006–November 2009
and December 2009–May 2014) based on the VANDU
IST operation period and fit multivariable models separ-
ately. Both periods included the same set of variables
described above with the only difference being the pres-
ence/absence of a variable assessing the use of the
VANDU IST in the previous 6 months (yes vs. no). We
determined the covariates to be included in the final
multivariable models using an a priori-defined model-
building procedure. The procedure started with all co-
variates that were associated with assisted injecting at
the level of p < 0.10 in unadjusted analyses, and pro-
ceeded using a backward selection process while two
variables (i.e., years injecting and accessing VANDU
IST) were forced to remain in the models. The final
multivariable models with the lowest quasi-likelihood
under the independence model criterion value were se-
lected [23].
Lastly, we also examined changes in the reasons for re-
quiring assisted injecting over time. Since the question
asking about reasons for assisted injecting was removed
from the questionnaire during some periods in the
follow-up, only the data collected during the first and
last 18 months of the study period (i.e., December
2005–May 2007 and December 2012–May 2014) were
available for this analysis. We used Pearson’s chi-squared
test (or Fisher’s exact test when one or more of the cells
contained expected values less than or equal to five) to
compare the reasons for assisted injecting between the
two 18-month periods. All p values were two-sided. All
statistical analyses were performed using the SAS soft-
ware version 9.4 (SAS, Cary, NC).
Results
Summary statistics
A total of 1119 participants, including 376 (33.6 %) fe-
male PWID, were included in this study. Of these, 151
(20.3 %) males and 127 (33.8 %) females reported requir-
ing assisted injecting in the previous 6 months at base-
line. Table 1 shows the baseline sample characteristics
stratified by requiring assisted injecting in the previous
6 months. As can be seen in Fig. 1, rates of requiring as-
sistance with injecting have decreased for both males
and females over time. In 2006, 37.0 % of females reported
assisted injecting in the previous 6 months compared to
25.6 % in 2014. Similarly, in 2006, 21.9 % of males re-
ported assisted injecting in the previous 6 months com-
pared to 13.8 % in 2014.
Primary analyses
The declining trends in assisted injecting were consistent
with the results of the multivariable GEE analyses. As
shown in Table 2, after an extensive confounder adjust-
ment, the calendar year of interview remained independ-
ently and negatively associated with assisted injecting
among both males (adjusted odds ratio [AOR] 0.95, 95 %
confidence interval [CI] 0.92–0.99) and females (AOR
0.93, 95 % CI 0.89–0.97).
Consistent with the GEE analyses, the sensitivity ana-
lysis using IEE also found declining trends in assisted
injecting among both males (for the calendar year of
interview, AOR 0.95, 95 % CI 0.91–0.99) and females
(AOR 0.93, 95 % CI 0.88–0.98).
Sub-analyses
In the multivariable GEE analyses of factors associated
with assisted injecting during two time periods, June
2006–November 2009 and December 2009–May 2014,
there were some persistent and changing correlates of
assisted injecting between the genders as well as between
the two time periods. Among males, during the first time
period, sex work (AOR 3.75, 95 % CI 1.68–8.33) and
injecting in public (AOR 1.41, 95 % CI 1.07–1.85) were in-
dependently associated with assisted injecting. During the
second time period, daily crystal meth injection (AOR
2.98, 95 % CI 1.93–4.61), injecting in public (AOR 2.00,
95 % CI 1.46–2.73), and syringe borrowing (AOR 1.88,
95 % CI 1.02–3.48) were independently associated with



















































Fig. 1 Rates of requiring assistance with injecting among PWID by year of interview. PWID people who inject drugs
Table 1 Baseline sample characteristics stratified by requiring assistance with injecting in the previous 6 months among PWID in
Vancouver, Canada (n = 1119)
Characteristic Males (n = 743) Females (n = 376)
Requiring assistance with injectinga p value Requiring assistance with injectinga p value
Yes (%) No (%) Yes (%) No (%)
151 (20.3) 592 (79.7) 127 (33.8) 249 (66.2)
Demographic and social characteristics
Age (median, IQR) 43 (36–48) 42 (35–48) 0.596 36 (28–43) 37 (29–45) 0.605
Caucasian 100 (66.2) 409 (69.1) 0.499 70 (55.1) 125 (50.2) 0.367
<High school diploma 78 (51.7) 249 (42.1) 0.039 65 (51.2) 141 (56.6) 0.368
In a stable relationship 40 (26.5) 148 (25.0) 0.683 55 (43.3) 96 (38.6) 0.390
Homelessa 63 (41.7) 230 (38.9) 0.519 57 (44.9) 86 (34.5) 0.051
Sex worka 7 (4.6) 11 (1.9) 0.069 54 (42.5) 102 (41.0) 0.822
Incarcerateda 29 (19.2) 115 (19.4) 0.951 28 (22.1) 33 (13.3) 0.031
Victim of violencea 50 (33.1) 137 (23.1) 0.013 43 (33.9) 51 (20.5) 0.007
Drug use-related characteristics
Years injecting (median, IQR) 20 (8–30) 19 (12–31) 0.347 12 (8–24) 16 (10–24) 0.044
≥Daily heroin injectiona 52 (34.4) 187 (31.6) 0.504 62 (48.8) 86 (34.5) 0.007
≥Daily cocaine injectiona 20 (13.3) 52 (8.8) 0.100 18 (14.2) 27 (10.8) 0.347
≥Daily crystal meth injectiona 14 (9.3) 24 (4.1) 0.009 8 (6.3) 9 (3.6) 0.229
≥Daily PO injectiona 8 (5.3) 47 (7.9) 0.269 7 (5.5) 12 (4.8) 0.772
Injecting in publica 77 (51.0) 242 (40.9) 0.021 67 (52.8) 92 (37.0) 0.003
Syringe borrowinga 15 (9.9) 56 (9.5) 0.860 22 (17.3) 21 (8.4) 0.011
Non-fatal overdosea 18 (11.9) 36 (6.1) 0.014 14 (11.0) 23 (9.2) 0.608
Accessed VANDU Injection
Support Teama
26 (17.2) 67 (11.3) 0.014 17 (13.4) 26 (10.4) 0.574
Ever learned safe injection technique
by healthcare provider
34 (22.5) 124 (21.0) 0.932 37 (29.1) 45 (18.1) 0.026
PWID people who inject drugs, IQR interquartile range, PO prescription opioid, VANDU Vancouver Area Network of Drug Users
aActivities in the previous 6 months
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assisted injecting. Among females, during the first time
period, sex work (AOR 1.45, 95 % CI 1.08–1.93), injecting
in public (AOR 1.97, 95 % CI 1.48–2.62), and syringe bor-
rowing (AOR 1.53, 95 % CI 1.10–2.11) were independ-
ently associated with requiring assistance with injecting.
During the second time period, daily heroin injection
(AOR 1.63, 95 % CI 1.17–2.28), injecting in public (AOR
1.45, 95 % CI 1.08–1.96), and syringe borrowing (AOR
2.15, 95 % CI 1.24–3.74) were independently associated
with assisted injecting.
Table 3 shows reasons for assisted injecting during the
first and last 18 months of the study period, December
Table 2 Univariable and multivariable GEE analyses of factors associated with requiring assistance with injecting among PWID in
Vancouver, Canada (n = 1119)
Characteristic Males Females
Unadjusted OR Adjusted OR Unadjusted OR Adjusted OR
(95 % CI) (95 % CI) (95 % CI) (95 % CI)
Interview year
(per year later) 0.95 (0.92–0.99) 0.95 (0.92–0.99) 0.90 (0.87–0.94) 0.93 (0.89–0.97)
Ethnicity
(Caucasian vs. other) 1.09 (0.80–1.49) 1.29 (0.91–1.81)
Education
(<high school diploma vs. ≥high school diploma) 1.14 (0.85–1.53) 0.95 (0.66–1.35)
Currently in a stable relationship
(yes vs. no) 1.20 (0.99–1.47) 1.05 (0.86–1.28)
Homelessa
(yes vs. no) 1.10 (0.91–1.32) 1.53 (1.23–1.90)
Sex worka
(yes vs. no) 2.67 (1.48–4.80) 2.17 (1.18–3.99) 1.48 (1.21–1.82)
Incarcerateda
(yes vs. no) 1.08 (0.86–1.34) 1.57 (1.19–2.09)
Victim of violencea
(yes vs. no) 1.35 (1.13–1.62) 1.24 (1.03–1.48) 1.56 (1.26–1.93) 1.31 (1.06–1.62)
Years since first injection
(per 10 years longer) 0.85 (0.75–0.97) 0.60 (0.49–0.73) 0.80 (0.65–0.98)
Heroin injectiona
(≥daily vs. <daily) 1.37 (1.15–1.63) 1.53 (1.23–1.90)
Cocaine injectiona
(≥daily vs. <daily) 1.56 (1.23–1.98) 0.92 (0.70–1.22)
Crystal meth injectiona
(≥daily vs. <daily) 2.11 (1.49–2.99) 2.20 (1.54–3.14) 0.99 (0.53–1.87)
PO injectiona
(≥daily vs. <daily) 1.01 (0.77–1.33) 0.98 (0.65–1.48)
Injecting in publica
(yes vs. no) 1.67 (1.41–1.97) 1.56 (1.31–1.85) 1.90 (1.57–2.30) 1.59 (1.29–1.96)
Syringe borrowinga
(yes vs. no) 1.38 (1.07–1.77) 1.96 (1.54–2.49) 1.47 (1.14–1.91)
Non-fatal overdosea
(yes vs. no) 1.56 (1.20–2.03) 1.23 (0.89–1.70)
Ever learned safe injection technique by healthcare provider
(yes vs. no) 1.05 (0.75–1.47) 1.93 (1.26–2.96) 1.80 (1.16–2.79)
PWID people who inject drugs, PO prescription opioid, OR odds ratio, CI confidence interval
aActivities/events in the past 6 months
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2005–May 2007 and December 2012–May 2014. As
shown, the three most common reasons for males re-
quiring assistance with injecting during the first
18 months included having bad veins/no veins (40.4 %),
jugular injection (21.2 %), and a lack of injection tech-
nique (20.5 %). In contrast, during the last 18 months,
the ranking slightly changed, including jugular injection
(33.3 %), bad veins/no veins (30.8 %), being anxious/
dope sick (14.1 %), and vision or other disability
(14.1 %). Significantly more males reported jugular injec-
tion to be a reason for assisted injecting in the second
compared to first period (p = 0.045). Among females, the
most common reasons during the first 18 months in-
cluded having bad veins/no veins (41.7 %), jugular injec-
tion (37.4 %), and a lack of injection technique (16.5 %).
Again, the ranking during the last 18 months slightly
changed and included jugular injection (45.0 %), bad
veins/no veins (30.0 %), and being anxious/dope sick
(21.7 %). Significantly more females reported being anx-
ious/dope sick to be a reason for assisted injecting in the
second compared to first time period (p = 0.016).
Discussion
In our study, rates of assisted injecting in the previous
6 months have declined between 2006 and 2014 for both
males (21.9 to 13.8 %) and females (37.0 to 25.6 %). The
declining trends were consistent with the results of mul-
tivariable GEE analyses in which, after extensive con-
founder adjustments, the calendar year of interview
remained independently and negatively associated with
assisted injecting among both genders. Further, syringe
borrowing remained independently and positively associ-
ated with assisted injecting throughout the study period
among females and in more recent years among males.
In the last 18-month period (between December 2012
and May 2014), the top three commonly reported rea-
sons for assisted injecting were similar between males
and females and included jugular injection, bad veins/no
veins, and being anxious/dope sick. For both genders,
proportions of participants reporting a lack of injection
technique as a reason for assisted injecting significantly
decreased in more recent years.
We have demonstrated a significant decline in the
rates of assisted injecting for both male and female
PWID over time even after adjusting for a range of po-
tential confounders. To our knowledge, this is the first
study examining trends in rates of assisted injecting over
time. The declining rates among PWID in this setting
are encouraging and may be related to increased aware-
ness of the risks associated with assisted injecting due to
improved access to harm reduction information and in-
terventions. Although the present study did not directly
examine whether access to such interventions helped
PWID stop assisted injecting, our findings that propor-
tions of PWID reporting “a lack of injection technique”
as a reason for requiring assisted injecting significantly
decreased among both genders in more recent years
suggest that this might have been the case for some
PWID. However, it is important to note that rates of
assisted injecting in recent years continue to be high
despite the decline demonstrated in this study. This is
particularly true for females, which is consistent with
previous studies demonstrating higher rates of assisted
injecting among females than males [1, 2, 4]. Research
has highlighted the social and structural context within
which assisted injecting commonly occurs, including the
role of social and interpersonal dynamics as well as so-
cial rules of providing money or drugs in exchange for
assistance [20]. For females, assisted injecting is often a
feature of intimate or romantic relationships where male
partners commonly control the drugs to be injected [14,
20]. This has been argued to further subordinate women
within drug scenes and increasing their vulnerability to
negative health consequences such as blood-borne infec-
tions [11, 24, 25]. Thus, we recommend that future in-
terventions examine ways of addressing the gender
disparity in rates of assisting injecting, including consid-
eration of the social and structural context.
Our findings support the existing literature by demon-
strating that syringe borrowing has continued to be
Table 3 Reasons for assisted injecting among PWID during two time periods (December 2005–May 2007 and December 2012–May 2014)










151 (65.9) 78 (34.1) 115 (65.7) 60 (34.3)
Lack of injection technique 31 (20.5) 8 (10.3) 0.050 19 (16.5) 2 (3.3) 0.013
Bad veins/no veins 61 (40.4) 24 (30.8) 0.153 48 (41.7) 18 (30.0) 0.128
Anxious/dope sick 22 (14.6) 11 (14.1) 0.924 10 (8.7) 13 (21.7) 0.016
Jugular injection 32 (21.2) 26 (33.3) 0.045 43 (37.4) 27 (45.0) 0.329
Vision or other disability 24 (15.9) 11 (14.1) 0.721 17 (14.8) 7 (11.7) 0.570
Other reasons 7 (4.6) 9 (11.5) 0.052 4 (3.5) 1 (1.7) 0.662
PWID people who inject drugs
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common among PWID requiring assistance with inject-
ing, particularly among women. In the context of intim-
ate relationships, qualitative findings have demonstrated
that women are often injected by controlling “boy-
friends” [11]. This increases the likelihood that boy-
friends will inject themselves first and then using the
same syringe on them after. In other words, gendered
power dynamics play an important role in increasing the
risk of syringe borrowing among women who rely on
assisted injecting. A concerning finding of our study is
that the association between assisted injecting and syr-
inge borrowing appears to have strengthened in recent
years (compared to the first time period studied). We
hypothesize that this may be due to a lack of specific in-
terventions targeting syringe sharing among those who
require assistance with injecting.
Our study demonstrates some noteworthy trends in
drug use patterns associated with assisted injecting over
time. Consistent with previous studies [26], injecting in
public was identified as a persistent correlate of assisted
injecting for both males and females throughout the
study period. This is concerning as injecting safely in
public is often challenged by unhygienic locations, inter-
ruption, violence, and police presence [26–28], all of
which increase risks to the harmful effects of assisted
injecting. Our study also highlights some changing
trends in drug use patterns. Daily crystal meth injection
was identified as an independent correlate of assisted
injecting among males in recent years. There has been
an increasing trend in crystal meth injections in Vancou-
ver in recent years [29]. People who inject drugs of a
short half-life, such as crystal meth, tend to inject many
times a day and are vulnerable to vascular damage and
blood-borne disease acquisition [30]. They may also sub-
sequently progress to injecting in more risky ways, such
as the jugular vein injecting [30], which is associated
with requiring assistance with injecting [31]. Our finding
that jugular injection as a reason for assisted injecting
has increased among males in recent years supports this
hypothesis, although loss of access to peripheral veins as
the VIDUS cohort ages is another possible explanation
for transitioning to jugular injections. Among females,
daily heroin injection was identified as an independent
correlate of assisted injecting in recent years, and anx-
iousness and dope sickness as a reason for requiring as-
sistance with injecting has also increased in recent years
among females. Dope sickness is common in people
withdrawing from heroin; thus, the increase in anxious-
ness and dope sickness is consistent with the emergence
of daily heroin injection as an independent correlate of
assisted injecting among females. However, our study
was unable to examine why different drugs were identi-
fied as independent correlates between the genders. Fur-
ther qualitative research is needed to explore this issue.
The findings presented in this study have a number of
important implications for policy and research. We agree
with previous researchers [1, 11, 12] that allowing
assisted injecting at SIFs would result in potential health
benefits for PWID. Not only would it likely decrease the
overall risky rate of assisted injecting (e.g., through ex-
tending the reach of the SIFs to a large subgroup of
PWID, who require manual assistance with injecting and
are at a heightened risk of harms associated with assisted
injecting due to the social and structural factors), allow-
ing assisted injecting at SIFs would also decrease the
number of PWID who inject in public outdoor spaces
thereby decreasing their vulnerability to harms associ-
ated with public outdoor assisted injecting [12]. Further-
more, permitting assisted injecting at SIFs would also
provide a significant sub-population of PWID with ac-
cess to clean syringes, thereby reducing their risk of
blood-borne infections. Indeed, a previous evaluation of
an unsanctioned peer-run SIF that allowed assisted
injecting demonstrated the feasibility and potential bene-
fits of this approach [32], indicating that it reshaped the
social and structural contexts surrounding assisted injec-
tion to reduce exposure to HIV risks and drug scene
violence. Secondly, previous studies have also demon-
strated that trained peer educators can provide helpful
education and safer injections to PWID who require as-
sistance injecting [3, 11]. Therefore, access to safe peer-
driven assisted injecting services both within SIFs as well
as in the community, such as the VANDU IST, should
be promoted.
This study has some limitations. First, as the VIDUS
study is not a random sample, our study findings may
not be generalizable to PWID at large. Second, the self-
reported data may have been affected by responding
bias, including socially desirable responding and recall
bias. If these sources of bias were present, the true
prevalence of risk behaviors assessed would be underes-
timated, which would bias our findings towards the null.
Third, as with all observational research, the estimated
relationships between the explanatory variables and
assisted injecting may be under the influence of unmeas-
ured confounding, although we sought to address this
bias through multivariable adjustment involving key po-
tential demographic, behavioral, social/structural, and
environmental confounders.
Conclusions
In summary, our study demonstrated that rates of assisted
injecting have significantly declined among our sample of
PWID in Vancouver between 2006 and 2014, which is en-
couraging as assisted injecting is a major risk factor for a
number of negative health consequences. However, rates
of assisted injecting remain high, especially among
women. We urge policy makers to reconsider the legal
Pedersen et al. Harm Reduction Journal  (2016) 13:2 Page 7 of 8
framework of existing SIFs to allow assisted injecting as
this would reduce a number of harmful consequences for
some of the most marginalized and vulnerable PWID.
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